Press Releases
Calidi is at the forefront of the genetic medicine revolution in cancer and other indications
Read the Latest
Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”),…
Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock
SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi”…
Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results
Announced FDA Clearance of the Northwestern University IND Application for NeuroNova (CLD-101) Clinical Trial in…
Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences
– RTNova, an innovative systemic antitumor enveloped virotherapy, unlocks new possibilities in cancer therapy –…
Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi”…
Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma
Trial will evaluate multiple doses of CLD-101 for the treatment of newly diagnosed high-grade glioma…